Solara Active Pharma Sciences Q1 FY27: net profit up 55% to ₹16.31 crore, revenue up 20%
Solara Active Pharma Sciences (BSE: SOLARA) said it has published its Q1 FY27 results (consolidated), reporting revenue of ₹382 crore (+19.6% year on year), net profit of ₹16.31 crore (+55.0%), earnings per share of ₹3.52. The company is valued at about…
What happened
Solara Active Pharma Sciences (BSE: SOLARA) informed the stock exchanges on 16 October 2026 at 01:36 PM that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹382 crore (+19.6% year on year), net profit of ₹16.31 crore (+55.0%), earnings per share of ₹3.52.
From the filing: "Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ...."
Company snapshot
Solara Active Pharma Sciences is a small-cap company, with a market value of about ₹3,564 crore.
The stock last traded at ₹738.7, against a 52-week range of ₹422–₹774 (4.6% below the high).
Before this filing the shares had moved −9.4% over the month and +13.7% over three months. Average daily turnover over the last 20 sessions was about ₹20.07 crore.
Promoters held 41.93% at the end of Q1 FY27, down 0.07% points from the previous quarter; 37.11% of promoter shares were pledged. Foreign institutions owned 11.52% and domestic institutions 3.74%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 319 | 10.5 | 2.46 |
| Q2 FY26 | 314 | -10.1 | -2.36 |
| Q3 FY26 | 349 | -17.4 | -3.98 |
| Q4 FY26 | 387 | 9.6 | 2.2 |
| Q1 FY27 | 382 | 16.3 | 3.52 |
What history shows
BCEIE's records show 2 previous results filings from the company since May 2026.
After those filings, the stock fell 5.9% on average the next trading day and was down 3.6% on average after five days (2 filings with price data).
Market-wide, 9,564 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 24 Jul 2026 | Submission Of Machine Readable Copy Of Financial Results For The… | −3.6% | −1.9% |
| 23 Jul 2026 | Inter alia, to consider and approve the unaudited Standalone and… | −8.2% | −5.3% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 16 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Solara Active Pharma Sciences ESG Rating Upgrade FY26
- Solara Active Pharma to host analyst call on Oct 16 for Q2FY27 results
- Solara Pharma approves forfeiture notice for unpaid rights shares
- Solara Active Pharma (NSE:SOLARA) Q2 FY27 Depository Certificate Filed
- Solara Active Pharma Sciences Ltd Reports ₹28.46 Crore Consolidated Profit In Q2
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.